Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Terminated 5Unknown 2Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Carcinoma, Non-Small-Cell Lung 22Cholangiocarcinoma 21Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Neoplasms 6Hodgkin Disease 6Gallbladder Neoplasms 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

Bevacizumab 9pembrolizumab 5lenvatinib 5durvalumab 5atezolizumab 5tremelimumab 3fludarabine 3camrelizumab 3apatinib 3Ipilimumab 3Cyclophosphamide 3regorafenib 2Riluzole 2Radiotherapy 2Nivolumab 2Magnetic Resonance Imaging 2Idarubicin 2Blood Specimen Collection 2Biopsy 2yttrium chloride 1trastuzumab deruxtecan 1spartalizumab 1sintilimab 1pertuzumab 1ferric carboxymaltose 1epigallocatechin gallate 1donafenib 1cemiplimab 1brodalumab 1Yttrium-90 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liver Neoplasms × Gemcitabine × Clear all
NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

AHS Cancer Control Alberta

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡